Your browser doesn't support javascript.
loading
Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop.
Bruysters, Martijn W P; Schiffelers, Marie-Jeanne; Hoonakker, Marieke; Jungbaeck, Carmen; Ragan, Ian; Rommel, Eddy; van der Stappen, Ton; Viviani, Laura; Hessel, Ellen V; Akkermans, Arnoud M; Vandebriel, Rob J.
Afiliación
  • Bruysters MWP; National Institute of Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: martijn.bruysters@rivm.nl.
  • Schiffelers MJ; Utrecht University School of Governance (USBO), Bijlhouwerstraat 6, 3511 ZC Utrecht, The Netherlands. Electronic address: M.J.W.A.Schiffelers@uu.nl.
  • Hoonakker M; Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands. Electronic address: marieke.hoonakker@intravacc.nl.
  • Jungbaeck C; Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, D-63225 Langen, Germany. Electronic address: Carmen.Jungbaeck@pei.de.
  • Ragan I; NC3Rs Board, Gibbs Building, 215 Euston Road, London NW1 2BE, UK. Electronic address: ian.ragan1@btinternet.com.
  • Rommel E; Rommel Consulting Partners, B-1370 Jodoigne, Belgium. Electronic address: erommel@rommel-consulting.be.
  • van der Stappen T; Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands. Electronic address: aj.vd.stappen@cbg-meb.nl.
  • Viviani L; Independent Consultant, Switzerland. Electronic address: vivianilaur@gmail.com.
  • Hessel EV; National Institute of Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: ellen.hessel@rivm.nl.
  • Akkermans AM; National Institute of Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: arnoud.akkermans@rivm.nl.
  • Vandebriel RJ; National Institute of Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: rob.vandebriel@rivm.nl.
Biologicals ; 48: 1-5, 2017 Jul.
Article en En | MEDLINE | ID: mdl-28666717
ABSTRACT
Safety and potency assessment for batch release testing of established vaccines still relies partly on animal tests. An important avenue to move to batch release without animal testing is the consistency approach. This approach is based on thorough characterization of the vaccine, and the principle that the quality of subsequent batches is the consequence of the application of consistent production of batches monitored by a GMP quality system. Efforts to implement the consistency approach are supported by several drivers from industry, government, and research, but there are also several barriers that must be overcome. A workshop entitled "Consistency Approach, Drivers and Barriers" was organized, which aimed to discuss and identify drivers and barriers for the implementation of the 3Rs in the consistency approach from three different perspectives/domains (industry, regulatory and science frameworks). The workshop contributed to a better understanding of these drivers and barriers and resulted in recommendations to improve the overall regulatory processes for the consistency approach. With this report, we summarise the outcome of this workshop and intend to offer a constructive contribution to the international discussion on regulatory acceptance of the consistency approach.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Control de Calidad / Vacunas / Industria Farmacéutica Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biologicals Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Control de Calidad / Vacunas / Industria Farmacéutica Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biologicals Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article